Is lapatinib officially included in medical insurance? What is the reimbursement status?

Although Lapatinib has been approved for marketing in China and is widely used in the treatment of HER2-positive breast cancer, it has not yet been included in the National Basic Medical Insurance Drug List. This means that patients still have to bear all costs out of pocket when using the drug and cannot receive direct reimbursement support through ordinary medical insurance. The common specification of lapatinib on the market is 0.25g*70 tablets. The price of a single box is usually between 5,000 yuan and 6,000 yuan. The economic pressure caused by long-term use is not easy for most patient families.

The lack of coverage by medical insurance limits the clinical popularity of lapatinib, especially among low- and middle-income patients. This situation objectively affects the long-term compliance and treatment effects of patients. Although its clinical efficacy has been verified in multiple international studies, and is especially suitable for patients with HER2-positive breast cancer who have developed resistance or relapse after trastuzumab treatment, the actual user population is limited due to the high drug price and the lack of reimbursement by medical insurance.

Some cities or provincial medical insurance may introduce limited support measures for policies such as special disease outpatient clinics and targeted drug special funds. However, patients are usually required to submit diagnosis certificates of special diseases, prescription information and related approval materials. The process is relatively complicated and does not cover the entire country. Therefore, before lapatinib is not included in medical insurance, if patients have treatment needs, it is recommended to consult the medical insurance bureau of their city or the medical insurance department of the hospital to learn whether there are local support policies or assistance channels.

In the future, as the national medical insurance negotiation mechanism continues to advance and the drug patent period approaches, it is expected that the price of lapatinib will be reduced and medical insurance coverage will be achieved. Once the drug is included in the medical insurance catalog, its clinical accessibility will be greatly improved, patients' financial pressure will be relieved, and the treatment landscape for HER2-positive breast cancer will be improved.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html